Form 4: IN8BIO, INC. Executive Kate Rochlin Reports Changes in Beneficial Ownership

Chief Operating Officer Kate Rochlin reports transactions involving IN8BIO, INC. warrants and common stock, including amendments to warrant terms.

Summary

• Kate Rochlin, Chief Operating Officer of IN8BIO, INC., filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• The reported transactions include the acquisition and disposal of common stock and Series A and B warrants.
• On April 27, 2025, Rochlin acquired Series A and B warrants and disposed of old warrants due to amendments in exercise prices and expiration dates.
• Specifically, the exercise price of Series A warrants was reduced from $0.45 to $0.1844 per share, and the expiration date was amended to May 2, 2025.
• Similarly, the exercise price of Series B warrants was reduced from $1.50 to $0.45 per share.
• On April 30, 2025, Rochlin exercised 12,295 Series A warrants at a price of $0.1844, resulting in the acquisition of 12,295 shares of common stock.
• Following these transactions, Rochlin directly owns 55,169 shares of common stock and 12,295 Series B warrants.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing changes in beneficial ownership. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about changes in insider ownership, which can influence investor confidence.

Key Dates

Keywords

Form 4, IN8BIO, Kate Rochlin, Beneficial Ownership, Warrants, Common Stock, Securities, Amendment